Acute Myelomonocytic Leukemia
Symptoms, Doctors, Treatments, Advances & More

Acute Myelomonocytic Leukemia Overview

Save information for later
Sign Up

Learn About Acute Myelomonocytic Leukemia

View Main Condition: Leukemia

What is the definition of Acute Myelomonocytic Leukemia?
A rare acute myeloid leukemia disorder characterized by increased blast cells (myeloblasts, monoblast, and/or promonoblasts), representing more than 20% of the total bone marrow (BM) or peripheral blood differential counts, with 20-80% of BM cells being of monocytic lineage. Clinical presentation is the result of bone marrow involvement and extramedullary infiltration by the leukemic cells and includes asthenia, pallor, fever, dizziness, respiratory symptoms, easy bruising, bleeding disorders, and neurological deficits. Gingival hyperplasia, organomegaly, especially hepatosplenomegaly, and lymphadenopathy may also be associated.
What are the alternative names for Acute Myelomonocytic Leukemia?
  • Acute myelomonocytic leukemia
  • Acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)
  • AML M4
  • AML-M4
  • AMMoL
  • Acute myeloblastic leukemia type 4
  • AML with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)
  • AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22)
  • Acute myelomonocytic leukemia
  • CBFB-MYH11
Who are the top Acute Myelomonocytic Leukemia Local Doctors?
Elite in Acute Myelomonocytic Leukemia
Elite in Acute Myelomonocytic Leukemia
Referral may be required
1425 Northwest 10th Avenue, 
Miami, FL 
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

His research focuses on patients with myelodysplastic syndromes (MDS) and older adults with acute myeloid leukemia (AML). Dr. Sekeres is rated as an Elite provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. He is also highly rated in 23 other conditions, according to our data. His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Sekeres is currently accepting new patients.

Elite in Acute Myelomonocytic Leukemia
Elite in Acute Myelomonocytic Leukemia
Referral may be required

University Of Texas MD Anderson Cancer Center

1515 Holcombe Blvd Unit 428, 
Houston, TX 
713-794-4392
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Naval Daver is an Oncologist practicing medicine in Houston, Texas. Dr. Daver is rated as an Elite provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. He is also highly rated in 39 other conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

 
 
 
 
Learn about our expert tiers
Learn More
Distinguished in Acute Myelomonocytic Leukemia
Distinguished in Acute Myelomonocytic Leukemia
Referral may be required

Avera Medical Group Oncology & Hematology — Aberdeen

310 S Penn St, Suite 106, 
Aberdeen, SD 
605-622-8700
Languages Spoken:
English
See accepted insurances

Dr. Richard Conklin is an oncologist/hematologist at Avera Medical Group Oncology & Hematology Aberdeen. Dr. Conklin is rated as a Distinguished provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. He is also highly rated in 90 other conditions, according to our data. His clinical expertise encompasses Acute Myelomonocytic Leukemia, Familial Colorectal Cancer, Lynch Syndrome, Paget Disease of the Breast, and Bone Marrow Aspiration. Dr. Conklin is board certified in American Board Of Internal Medicine American Board Of Internal Medicine-Medical Oncology.

View All Doctors
What are the latest Acute Myelomonocytic Leukemia Clinical Trials?
A Phase I/II Study Evaluating Escalating Doses of 211At-Labeled Anti-CD45 MAb BC8-B10 (211At-BC8-B10) Followed by Related Haplo-Identical Allogeneic Hematopoietic Cell Transplantation for High-Risk Acute Leukemia or Myelodysplastic Syndrome (MDS)
A Phase I/II Study Evaluating Escalating Doses of 211At-Labeled Anti-CD45 MAb BC8-B10 (211At-BC8-B10) Followed by Related Haplo-Identical Allogeneic Hematopoietic Cell Transplantation for High-Risk Acute Leukemia or Myelodysplastic Syndrome (MDS)
Who is this study for: Adult patients with Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndromes, or Mixed Phenotype Acute Leukemia
Enrollment Status: Recruiting
Publish Date: June 16, 2026
Intervention Type: Drug, Radiation, Biological, Procedure
Study Drugs: Cyclophosphamide, Mycophenolate Mofetil, Fludarabine, Tacrolimus, Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Filgrastim
Study Phase: Phase 1/Phase 2

Summary: This phase I/II trial studies the side effects and best dose of a radioactive agent linked to an antibody (211At-BC8-B10) followed by donor stem cell transplant in treating patients with high-risk acute leukemia or myelodysplastic syndrome that has come back (recurrent) or isn't responding to treatment (refractory). 211At-BC8-B10 is a monoclonal antibody that may interfere with the ability of canc...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
Enrollment Status: Recruiting
Publish Date: June 04, 2026
Intervention Type: Device
Study Phase: Phase 2

Summary: This study will assess the safety, efficacy, and feasibility of ⍺/β CD3+ T-cell and CD19+ B-cell depletion in allogeneic stem cell transplantation in patients with acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), juvenile myelomonocytic leukemia (JMML), high risk myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML) and lymphoma. Subjects will receive an allogeneic stem cel...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center